BridgeBio Pharma, Inc.BBIO

Market cap

$14.5B

P/E ratio

	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	364	356	394	417	395	683
Marketable securities, current	182	251	394	52	-	-
Total cash & short-term investments	546	607	788	468	395	683
Accounts receivable, net	-	-	-	-	-	5
Total current assets	569	643	889	549	478	721
Property, plant and equipment, net	6	20	30	15	12	7
Marketable securities, non-current	31	-	-	-	-	-
Total non-current assets	63	61	124	74	69	199
Total assets	632	704	1,013	623	546	919
Accounts payable	9	9	12	12	11	10
Long-term debt, current	-	1	-	-	-	-
Total current liabilities	60	96	135	121	144	154
Long-term debt, non-current	92	92	431	431	446	437
Total non-current liabilities	95	500	1,743	1,747	1,745	2,223
Total liabilities	156	596	1,878	1,868	1,889	2,377
Common stock and paid-in capital	0	0	0	0	0	0
Retained earnings	-440	-889	-1,437	-1,918	-2,561	-3,096
Stockholders' equity	474	106	-867	-1,243	-1,343	-1,458
Total debt	92	94	431	431	446	437
Net debt	-454	-513	-357	-37	52	-246
D/E ratio (%)	19.4	88.4	-49.7	-34.7	-33.2	-30